RxDoctor Payments Data

Alphonza Vester, MD

Internal Medicine · Lafayette, ALNPI 1447311295

Payments from drug & device makers

$1,748in general payments, 2019–2025

Across 89 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$450
  • Otsuka America Pharmaceutical, Inc.$312
  • Neurocrine Biosciences, Inc.$267
  • AbbVie$233
  • Alkermes, Inc.$221
  • Johnson & Johnson$156
  • plus $109 from 5 others

What the payments were for

  • Food & beverage$1,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,748 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$14,372
Medicare patients
58
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate87$269,439
IngrezzaValbenazine Tosylate23$183,007
RybelsusSemaglutide43$100,655
JanuviaSitagliptin Phosphate33$34,862
FarxigaDapagliflozin Propanediol26$30,219
OzempicSemaglutide11$26,994
Lurasidone Hcl29$15,606
SymbicortBudesonide/Formoterol Fumarate18$8,667
Fluphenazine Hcl30$7,734
Aripiprazole60$7,058
Diclofenac Sodium46$3,402
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,146
Albuterol Sulfate HfaAlbuterol Sulfate57$2,557
Fluphenazine Decanoate27$2,278
Divalproex Sodium84$2,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$156$269,43987 claims
Neurocrine Biosciences, Inc.Ingrezza$267$183,00723 claims
Novo NordiskRybelsus, Ozempic$450$127,64854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Lafayette

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →